Zambon heading to US market with €500m acquisition
Zambon is set to acquire respiratory company Breath Therapeutics for up to €500m to complement its respiratory pipeline and get access to the US market.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1998 entries already.
Entries by Thomas Gabrielczyk
Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
3P Pharma finds new major investor
Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing 3P with leap in terms of capacity, equipment, technology, and talent, Keensight is expected to consolidate 3Ps position as one of few mid-sized CDMOs on the international market that offers commercial manufacturing capabilities.
"We are extremely enthusiastic to work with Keensight Capita at such a crucial moment for our industry," said Dámaso Molero, CEO of 3P Biopharmaceuticals. "With their global footprint and their expertise inthe biologics field, I am highly confident that Keensight team will help us reach significant milestones in the coming years.
3P experienced a 23% annual revenue growth over the past 4 years, 10% above the rate the biological CDMO market is to grow from 2018-2022. The fully integrated specialist in process development and GMP-compliant manufacturing biologics and cell therapy products is further being funded by Sodena, the financial business development instrument of the Government of Navarra.
Curetis lower respiratory tract panel ready for FDA clearance
Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Controlled human malaria infection trials
Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
European Biotechnology Guide now available on app!
The European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
Making every cent in testing count
Its no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
Bioeconomy: just a way to set up a smarter agriculture?
Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
Biotech company Galapagos improves high-content screening (HCS) in scleroderma with IN Carta Phenoglyphs image analysis
Galapagoss mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.